Baxter’s dominant 60% market share in U.S. IV fluids provides a critical healthcare infrastructure moat that’s difficult to replicate. With new CEO Andrew Hider’s automation expertise, Baxter is positioned to drive significant operational efficiency improvements.
What’s more, Baxter’s strategic focus following the Kidney Care divestiture provides ample resources for debt reduction, innovation investment, and potential shareholder returns. With earnings expected to keep growing this year and the company’s transformation strategy gaining momentum, the company is well-positioned to capitalize on the expanding medtech market while maintaining its mission-critical role in healthcare delivery.
Meanwhile, the stock trades at an attractive 9.6 times the company’s forward earnings forecast.
BAXTER INTERNATIONAL INC. (New York symbol BAX; www.baxter.com) makes specialized equipment for hospitals, including intensive-care-unit beds, operating tables, patient monitoring equipment and electronic diagnostic systems.
Baxter has narrowed its focus in the past few years.
For instance, in September 2023, the company sold for $4.25 billion (or $3.4 billion after taxes) its BioPharma division, whose products and services help drugmakers manufacture their products.
Then, on February 1, 2025, Baxter completed the sale of its Renal Care and Acute Therapies unit to investment firm Carlyle Group Inc. (New York symbol CG). Called Vantive, that business makes kidney dialysis machines and related equipment; it accounted for 30% of Baxter’s total revenue.
[ofie_ad]
The company originally planned to hand out shares in Vantive to its own shareholders, but it ultimately opted for the sale instead.
Baxter received $3.8 billion for Vantive.
As a result of these moves, Baxter now focuses on specialized equipment for hospitals, including intensive-care-unit beds, operating tables, patient monitoring equipment and electronic diagnostic systems.
Trading at just 9.6x forward earnings despite strong market position
In the quarter ended June 30, 2025, the company’s sales rose 4.3%, to $2.81 billion from $2.69 billion, a year earlier. Excluding one-time items, Baxter made $304 million, or $0.59 a share, up 29.9% from $234 million or $0.46.
Baxter will probably make $2.47 a share in 2025, and the stock trades at just 9.6 times that estimate. As a result of the recent asset sales, the company cut its quarterly dividend by 58.6%; the new annual rate of $0.68 still yields a solid 2.9%.
Recommendation in Spinoffs & Takeovers: Baxter International Inc. is a buy.